Polycythemia Vera – Current Treatment – Treatment Algorithms – Claims Data Analysis: Polycythemia Vera – Refreshed Dashboard 2021 (US)
MARKET OUTLOOK
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
QUESTIONS ANSWERED
What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed polycythemia vera patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PV patients?
How has ruxolitinib (Jakafi) been integrated into the treatment algorithm and what is its source of business?
What percentage of PV patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after the diagnosis?
What percentage of PV patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
What are the product-level compliance and persistency rates among drug-treated patients?
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients. In addition, the dashboard features multiple data refreshes after report publication.
Polycythemia Vera - Current Treatment - Treatment Algorithms - Claims Data Analysis: Polycythemia Vera - Refreshed Dashboard 2021 (US)
Treatment Algorithms CDA Polycythemia Vera 2021 Dashboard
Raina Priyadarshini, Ph.D.
Raina Priyadarshini, Ph.D., is a senior analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. Previously, she was an analyst in the biopharmaceutical industry, where she developed novel disease target-drug combinations for rare CNS and hematological disorders. Dr. Priyadarshini trained as a molecular biologist; her research focused on the interplay between tumor suppressor proteins and oncoproteins. She received her doctorate from the National Institute of Immunology.
